by: Parent Project Muscular DystrophyCommunity Update Call: Sarepta & Summit (October 2016)
Sarepta Therapeutics and Summit recently announced a license and collaboration agreement, which grants Sarepta the right to commercialize Summit’s utrophin modulators in Europe should they receive approval. This includes ezutromid, which is currently in the Phase 2 PhaseOut DMD trial. PPMD hosted a community update call with Sarepta and Summit on October 10, 2016.
